Prab: CSV import

2025-02-17T02:04:56Z

CSV import

← Older revision		Revision as of 02:04, 17 February 2025
Line 21:		Line 21:

	{{medicine-stub}}		{{medicine-stub}}
			<gallery>
			File:Darglitazone_structure.svg\|Structure of Darglitazone
			File:Darglitazone.png\|Darglitazone
			</gallery>

Prab: CSV import

2024-03-22T12:26:50Z

CSV import

New page

'''Darglitazone''' is a pharmaceutical compound that belongs to the class of drugs known as [[thiazolidinediones]], which are used primarily for the treatment of [[Type 2 diabetes]]. Thiazolidinediones work by increasing the sensitivity of liver, fat, and muscle cells to [[insulin]], thereby improving the management of [[blood glucose levels]] in patients with Type 2 diabetes. Despite its potential benefits, darglitazone is not widely used due to concerns over its safety profile and the availability of more effective or safer alternatives.

==Mechanism of Action==
Darglitazone functions as an agonist to the [[peroxisome proliferator-activated receptor gamma]] (PPARγ), a type of nuclear receptor that plays a crucial role in the regulation of fatty acid storage and glucose metabolism. Activation of PPARγ by darglitazone enhances the transcription of insulin-responsive genes that are involved in the control of glucose production, transport, and utilization, thereby reducing insulin resistance and lowering blood glucose levels.

==Clinical Uses==
The primary indication for darglitazone is the treatment of Type 2 diabetes, particularly in patients who have shown to be resistant to other treatments. However, its use has been limited by concerns over adverse effects and the development of more effective medications within the same class.

==Adverse Effects==
Like other thiazolidinediones, darglitazone has been associated with a range of adverse effects. These can include weight gain, edema, and an increased risk of heart failure. Its safety profile, particularly concerning cardiovascular risks, has led to a cautious approach in its use. Additionally, there have been concerns about the potential for increased risk of bladder cancer with drugs in this class, although the evidence is not conclusive.

==Regulatory Status==
Due to safety concerns and the availability of other treatment options, darglitazone has not achieved widespread approval by regulatory agencies such as the [[U.S. Food and Drug Administration]] (FDA) or the European Medicines Agency (EMA). Its use remains limited, and it is often not the first choice for the treatment of Type 2 diabetes.

==Conclusion==
While darglitazone represents an important development in the class of thiazolidinediones for the management of Type 2 diabetes, its clinical use has been overshadowed by concerns regarding its safety profile and the emergence of more effective alternatives. Ongoing research into the mechanisms of action and safety of thiazolidinediones continues to be important for the development of safer and more effective treatments for Type 2 diabetes.

[[Category:Thiazolidinediones]]
[[Category:Antidiabetic drugs]]
[[Category:Type 2 diabetes medications]]

{{medicine-stub}}

Darglitazone - Revision history

Prab: CSV import

Prab: CSV import